India, Oct. 16 -- Omeros Corp. (OMER) is down 12.03 percent, losing $2.26 to $16.53 on Friday. The decline follows a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use on the company's marketing authorization application for narsoplimab to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy. The decision followed a re-examination of the committee's original negative opinion issued in June 2026.
Omeros is currently trading at $16.53, down from the previous close of $18.79 after opening at $17.84. The stock has traded between $15.89 and $17.94 during the session on the Nasdaq. Trading volume stands at 1.43 million shares, compared with average volume of 1.70 million...